How a University of Bristol spin-off grew to become the first lab customer at Future Space.
Pertinax Pharma were the first company to take up laboratory spaces here at Future Space. Pertinax is a patent-protected, sustained release technology for chlorhexidine, a common antiseptic. It can be used as a filler component of materials for biomedical and other applications, as a component of topical agents, and as a coating for medical devices.
"Moving our operation to Future Space offers us the opportunity to expand our team as we look to develop Pertinax for new applications and markets.”
Stuart Gibson, Chief Financial Officer for Pertinax Pharma
Dr Michele Barbour and her research group at the University of Bristol School of Oral and Dental Sciences have been developing sustained efficacy antimicrobial materials for many years. In April 2015 Pertinax Pharma Ltd was established to commercialise the many and diverse applications of this proprietary CHX technology. Since their ambitious move to Future Space here in Bristol, the company is looking to expand into different markets such as application of the product in wound care and veterinary markets.
More Case Studies
Celebrating five years of Future Space
Five years ago Future Space became one of four university enterprise zones in the UK, co-located with UWE Bristol, as part of a pilot to see how having businesses on campus impacts better outcomes for both students and businesses. Find out more about what makes Future Space so great.
Five Years with Future Space: An interview with our Centre Manager, Parm Cory-Jones
Parm Cory-Jones has been with the Future Space team from the beginning. As we celebrate five years of the centre, we meet up with her to find out what makes Future Space so special.
Case Studies – Cerberus Security Laboratories
Cerberus Security Laboratories joined Future Space four years ago. We caught up with Director and Co-founder Andy Lindsay to talk about their journey and what they’re working on now.